Iran to quintuple anticancer nano-drug exports to Syria

TEHRAN, Nov. 08 (MNA) – CEO of an Iranian knowledge-based company active in producing anticancer nano-drugs said the company is planning to increase its exports to Syria fivefold in the current Iranian year.

Mahnaz Ghomi, CEO of the knowledge-based company active in producing the anticancer drug ‘SinaDoxosome’, told Mehr News that they have been producing the anticancer drugs through nanotechnology since 2011.

Noting that the company has managed to export 400 vials of SinaDoxosome (with each vial priced at $275) to Syrai in the last year, Ghomi added that they are planning to increase the exports five times more than the previous year, roughly 2,000 vials.  

She noted that the Iranian anticanser nano-drugs are priced 40 percent less than other countries’ exported drugs, adding that SinaDoxosome is considered as one of the main chemotherapy drugs for patients with breast and ovarian cancer; “it can also be used for treating bone marrow cancer and the Kaposi’s sarcoma cancer in patients with AIDS,” she said.

“SinaDoxosome is made of nanoliposomes carrying the anticancer drug Doxorubicin; with its mechanism of enhanced permeability and retention (EPR) effect, the drug targets the cancerous tumor tissue and increases its effectiveness and reduces the side effects,” she explained.

According to her, the Iranian version of this nano-drug is priced at about $234, while the foreign versions are marketed at $1200 and $700.

Iran is the fifth country in the world that has the technology to produce this type of anticancer nano-drug.  




News Code 111757


Your Comment

You are replying to: .
  • 3 + 5 =